BridgeBio Pharma Inc.

11.09-0.8400-7.04%Vol 2.02M1Y Perf -77.65%
Aug 9th, 2022 16:00 DELAYED
BID10.09 ASK12.47
Open11.60 Previous Close11.93
Pre-Market- After-Market11.58
 - -  0.49 4.42%
Target Price
20.57 
Analyst Rating
Strong Buy 1.14
Potential %
85.48 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/100/50 
Value Ranking
★★     45.49
Insiders Value % 3/6/12 mo.
-/100/-16 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/36 
Income Ranking
 —    -
Price Range Ratio 52W %
12.18 
Earnings Rating
Market Cap1.64B 
Earnings Date
4th Aug 2022
Alpha-0.01 Standard Deviation0.22
Beta0.79 

Today's Price Range

10.7711.88

52W Range

4.9855.16

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
39.67%
1 Month
10.02%
3 Months
83.31%
6 Months
17.98%
1 Year
-77.65%
3 Years
-58.74%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BBIO11.09-0.8400-7.04
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
93.70
-788.30
-778.30
-
-
RevenueValueIndustryS&P 500US Markets
16.92M
0.11
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.92-0.8111.96
Q01 2022-1.13-1.19-5.31
Q04 2021-0.83-1.01-21.69
Q03 2021-0.91-1.06-16.48
Q02 2021-0.93-0.6629.03
Q01 2021-0.87-1.18-35.63
Q04 2020-0.86-1.01-17.44
Q03 2020-0.97-0.98-1.03
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.92
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume2.02M
Shares Outstanding148.25K
Shares Float81.72M
Trades Count19.65K
Dollar Volume22.87M
Avg. Volume3.15M
Avg. Weekly Volume4.45M
Avg. Monthly Volume2.64M
Avg. Quarterly Volume2.37M

BridgeBio Pharma Inc. (NASDAQ: BBIO) stock closed at 11.09 per share at the end of the most recent trading day (a -7.04% change compared to the prior day closing price) with a volume of 2.02M shares and market capitalization of 1.64B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 396 people. BridgeBio Pharma Inc. CEO is Neil Kumar.

The one-year performance of BridgeBio Pharma Inc. stock is -77.65%, while year-to-date (YTD) performance is -33.51%. BBIO stock has a five-year performance of %. Its 52-week range is between 4.98 and 55.16, which gives BBIO stock a 52-week price range ratio of 12.18%

BridgeBio Pharma Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 123.68, a price-to-sale (PS) ratio of 76.45, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -64.57%, a ROC of -63.99% and a ROE of 84.26%. The company’s profit margin is -%, its EBITDA margin is -778.30%, and its revenue ttm is $16.92 Million , which makes it $0.11 revenue per share.

Of the last four earnings reports from BridgeBio Pharma Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.92 for the next earnings report. BridgeBio Pharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BridgeBio Pharma Inc. is Strong Buy (1.14), with a target price of $20.57, which is +85.48% compared to the current price. The earnings rating for BridgeBio Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BridgeBio Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BridgeBio Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.35, ATR14 : 1.08, CCI20 : 244.44, Chaikin Money Flow : 0.23, MACD : 0.39, Money Flow Index : 49.21, ROC : 20.63, RSI : 67.17, STOCH (14,3) : 88.37, STOCH RSI : 0.95, UO : 64.61, Williams %R : -11.63), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BridgeBio Pharma Inc. in the last 12-months were: Andrea John Ellis (Buy at a value of $100 680), Brian C. Stephenson (Option Excercise at a value of $0), Charles J. Homcy (Option Excercise at a value of $0), Douglas A. Dachille (Buy at a value of $245 584), Neil Kumar (Option Excercise at a value of $0), Richard H. Scheller (Option Excercise at a value of $0), Ronald J. Daniels (Buy at a value of $298 679), Ronald J. Daniels (Sold 11 745 shares of value $150 336 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (85.71 %)
6 (85.71 %)
6 (85.71 %)
Moderate Buy
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.14
Strong Buy
1.14
Strong Buy
1.14

BridgeBio Pharma Inc.

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

CEO: Neil Kumar

Telephone: +1 650 391-9740

Address: 421 Kipling Street, Palo Alto 94301, CA, US

Number of employees: 396

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

62%38%

TipRanks News for BBIO

Tue, 26 Jul 2022 16:35 GMT Analysts Top Healthcare Picks: BridgeBio Pharma (BBIO), Nutriband (NTRB)

- TipRanks. All rights reserved.

Fri, 20 May 2022 15:25 GMT Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Mustang Bio (MBIO)

- TipRanks. All rights reserved.

Fri, 04 Mar 2022 12:36 GMT BridgeBio Pharma (BBIO) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

Wed, 09 Feb 2022 19:55 GMT BridgeBio Pharma (BBIO) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

Mon, 24 Jan 2022 13:45 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), BridgeBio Pharma (BBIO) and Kinnate Biopharma (KNTE)

- TipRanks. All rights reserved.

News

Stocktwits